| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognitive Dysfunction | 29 | 2026 | 338 | 7.730 |
Why?
|
| Hypertension | 35 | 2024 | 1356 | 5.610 |
Why?
|
| Alzheimer Disease | 26 | 2026 | 878 | 5.510 |
Why?
|
| Cognition | 23 | 2026 | 829 | 4.030 |
Why?
|
| Blood Pressure | 26 | 2024 | 1345 | 3.900 |
Why?
|
| Cognition Disorders | 14 | 2017 | 556 | 3.570 |
Why?
|
| Cerebrovascular Circulation | 11 | 2020 | 487 | 3.230 |
Why?
|
| Antihypertensive Agents | 17 | 2024 | 414 | 2.780 |
Why?
|
| Lisinopril | 4 | 2023 | 27 | 1.930 |
Why?
|
| Renin-Angiotensin System | 5 | 2015 | 104 | 1.680 |
Why?
|
| tau Proteins | 8 | 2026 | 257 | 1.670 |
Why?
|
| Aged | 66 | 2026 | 21025 | 1.540 |
Why?
|
| Amyloid beta-Peptides | 8 | 2026 | 229 | 1.520 |
Why?
|
| Tetrazoles | 4 | 2023 | 70 | 1.520 |
Why?
|
| Benzimidazoles | 4 | 2023 | 161 | 1.450 |
Why?
|
| Aging | 10 | 2024 | 1242 | 1.120 |
Why?
|
| Middle Aged | 49 | 2026 | 28601 | 1.080 |
Why?
|
| Stress, Psychological | 4 | 2023 | 536 | 1.050 |
Why?
|
| Geriatrics | 6 | 2010 | 74 | 1.010 |
Why?
|
| Memory | 4 | 2022 | 314 | 1.000 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2022 | 133 | 0.950 |
Why?
|
| Neuropsychological Tests | 12 | 2026 | 960 | 0.950 |
Why?
|
| Peptide Fragments | 6 | 2026 | 687 | 0.930 |
Why?
|
| Aged, 80 and over | 24 | 2026 | 6797 | 0.920 |
Why?
|
| Male | 66 | 2026 | 64957 | 0.910 |
Why?
|
| Female | 70 | 2026 | 70963 | 0.900 |
Why?
|
| Computer Literacy | 1 | 2024 | 8 | 0.870 |
Why?
|
| Remote Consultation | 1 | 2024 | 23 | 0.860 |
Why?
|
| Apolipoprotein E4 | 4 | 2022 | 51 | 0.840 |
Why?
|
| Research Subjects | 1 | 2024 | 54 | 0.840 |
Why?
|
| Biomarkers | 16 | 2026 | 3385 | 0.830 |
Why?
|
| Humans | 94 | 2026 | 131163 | 0.820 |
Why?
|
| Brain | 12 | 2025 | 3175 | 0.740 |
Why?
|
| Prodromal Symptoms | 2 | 2020 | 10 | 0.740 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2022 | 214 | 0.690 |
Why?
|
| Executive Function | 5 | 2026 | 122 | 0.680 |
Why?
|
| Hemodynamics | 3 | 2018 | 810 | 0.670 |
Why?
|
| Regional Blood Flow | 2 | 2013 | 191 | 0.660 |
Why?
|
| Carbon Dioxide | 3 | 2023 | 270 | 0.660 |
Why?
|
| Mortality | 2 | 2015 | 264 | 0.650 |
Why?
|
| Cross-Sectional Studies | 10 | 2026 | 3829 | 0.650 |
Why?
|
| Carbolines | 1 | 2020 | 6 | 0.620 |
Why?
|
| Stroke | 2 | 2023 | 1061 | 0.600 |
Why?
|
| Internet | 4 | 2007 | 420 | 0.590 |
Why?
|
| Positron-Emission Tomography | 2 | 2023 | 279 | 0.580 |
Why?
|
| Cognitive Aging | 1 | 2018 | 8 | 0.570 |
Why?
|
| Age Factors | 11 | 2018 | 2825 | 0.550 |
Why?
|
| Leukoencephalopathies | 1 | 2018 | 63 | 0.540 |
Why?
|
| Blood Pressure Determination | 5 | 2013 | 118 | 0.530 |
Why?
|
| Psychomotor Performance | 1 | 2019 | 174 | 0.530 |
Why?
|
| Biphenyl Compounds | 4 | 2023 | 75 | 0.520 |
Why?
|
| Nerve Fibers, Myelinated | 2 | 2022 | 83 | 0.500 |
Why?
|
| Polymorphism, Genetic | 2 | 2010 | 776 | 0.500 |
Why?
|
| Stem Cells | 2 | 2026 | 702 | 0.500 |
Why?
|
| Longitudinal Studies | 7 | 2026 | 1490 | 0.480 |
Why?
|
| Health Status Disparities | 1 | 2019 | 282 | 0.480 |
Why?
|
| White Matter | 1 | 2018 | 219 | 0.470 |
Why?
|
| Risk Factors | 17 | 2020 | 11074 | 0.470 |
Why?
|
| Circadian Rhythm | 2 | 2009 | 327 | 0.470 |
Why?
|
| Life Style | 3 | 2007 | 456 | 0.450 |
Why?
|
| Attitude to Health | 2 | 2007 | 247 | 0.450 |
Why?
|
| Cohort Studies | 10 | 2024 | 5063 | 0.450 |
Why?
|
| Vascular Stiffness | 1 | 2015 | 76 | 0.430 |
Why?
|
| Renin | 1 | 2014 | 75 | 0.430 |
Why?
|
| Hypotension | 2 | 2020 | 187 | 0.420 |
Why?
|
| Aldosterone | 1 | 2014 | 56 | 0.420 |
Why?
|
| Respiration | 1 | 2014 | 117 | 0.410 |
Why?
|
| Follow-Up Studies | 9 | 2024 | 5196 | 0.400 |
Why?
|
| Proton Pump Inhibitors | 1 | 2017 | 326 | 0.400 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2010 | 57 | 0.390 |
Why?
|
| Oxidative Stress | 1 | 2018 | 791 | 0.380 |
Why?
|
| Diet | 3 | 2007 | 1121 | 0.380 |
Why?
|
| Amnesia | 2 | 2018 | 20 | 0.360 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2013 | 150 | 0.360 |
Why?
|
| Hydrochlorothiazide | 1 | 2012 | 67 | 0.350 |
Why?
|
| Gait | 2 | 2009 | 141 | 0.340 |
Why?
|
| Mental Recall | 2 | 2018 | 138 | 0.330 |
Why?
|
| Cholesterol | 2 | 2022 | 539 | 0.330 |
Why?
|
| Mobility Limitation | 1 | 2011 | 31 | 0.330 |
Why?
|
| Prevalence | 9 | 2024 | 2701 | 0.310 |
Why?
|
| Mood Disorders | 1 | 2011 | 129 | 0.310 |
Why?
|
| Treatment Outcome | 7 | 2017 | 12936 | 0.300 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2009 | 52 | 0.300 |
Why?
|
| Hypotension, Orthostatic | 2 | 2011 | 20 | 0.300 |
Why?
|
| Connectome | 2 | 2023 | 111 | 0.300 |
Why?
|
| Pulse Wave Analysis | 2 | 2022 | 48 | 0.300 |
Why?
|
| United States | 14 | 2026 | 12072 | 0.290 |
Why?
|
| Disease Progression | 5 | 2023 | 2200 | 0.280 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2026 | 3763 | 0.280 |
Why?
|
| Cardiovascular Diseases | 3 | 2011 | 2121 | 0.280 |
Why?
|
| Neuroimaging | 2 | 2023 | 385 | 0.280 |
Why?
|
| Double-Blind Method | 5 | 2022 | 1626 | 0.270 |
Why?
|
| Case-Control Studies | 5 | 2024 | 3359 | 0.260 |
Why?
|
| Computer-Assisted Instruction | 2 | 2007 | 58 | 0.260 |
Why?
|
| Community Health Nursing | 1 | 2007 | 4 | 0.260 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 468 | 0.250 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 4066 | 0.250 |
Why?
|
| Drug Monitoring | 1 | 2009 | 292 | 0.240 |
Why?
|
| Social Isolation | 1 | 2026 | 49 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2013 | 1618 | 0.240 |
Why?
|
| Loneliness | 1 | 2026 | 34 | 0.230 |
Why?
|
| Education, Distance | 1 | 2007 | 69 | 0.230 |
Why?
|
| Calcium, Dietary | 2 | 2003 | 38 | 0.230 |
Why?
|
| Lysophospholipids | 1 | 2025 | 45 | 0.230 |
Why?
|
| Nerve Net | 2 | 2018 | 254 | 0.220 |
Why?
|
| Ventricular Remodeling | 1 | 2026 | 155 | 0.220 |
Why?
|
| Proteomics | 4 | 2025 | 615 | 0.220 |
Why?
|
| Neurofilament Proteins | 1 | 2024 | 39 | 0.220 |
Why?
|
| Exercise Test | 1 | 2025 | 239 | 0.210 |
Why?
|
| Quality Assurance, Health Care | 2 | 2007 | 205 | 0.210 |
Why?
|
| Adult | 14 | 2025 | 31282 | 0.210 |
Why?
|
| Postural Balance | 1 | 2025 | 133 | 0.210 |
Why?
|
| Posture | 1 | 2005 | 138 | 0.210 |
Why?
|
| Benzothiadiazines | 1 | 2004 | 7 | 0.210 |
Why?
|
| Health Behavior | 1 | 2007 | 387 | 0.200 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2004 | 35 | 0.200 |
Why?
|
| Lower Extremity | 1 | 2025 | 185 | 0.200 |
Why?
|
| Coronary Artery Disease | 2 | 2020 | 887 | 0.200 |
Why?
|
| Regeneration | 1 | 2026 | 230 | 0.200 |
Why?
|
| Verbal Learning | 2 | 2019 | 67 | 0.200 |
Why?
|
| Essential Tremor | 1 | 2024 | 96 | 0.190 |
Why?
|
| Blood Flow Velocity | 2 | 2015 | 417 | 0.190 |
Why?
|
| Feeding Behavior | 2 | 2006 | 715 | 0.190 |
Why?
|
| Emotions | 1 | 2026 | 350 | 0.190 |
Why?
|
| Hyponatremia | 1 | 2004 | 73 | 0.190 |
Why?
|
| Research | 1 | 2024 | 264 | 0.190 |
Why?
|
| Education, Medical | 1 | 2007 | 293 | 0.190 |
Why?
|
| Educational Status | 1 | 2024 | 279 | 0.190 |
Why?
|
| Angiotensins | 1 | 2022 | 9 | 0.190 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2026 | 362 | 0.190 |
Why?
|
| Demography | 1 | 2023 | 237 | 0.190 |
Why?
|
| Geriatric Assessment | 4 | 2011 | 184 | 0.190 |
Why?
|
| Micronutrients | 1 | 2003 | 62 | 0.180 |
Why?
|
| Troponin T | 1 | 2024 | 259 | 0.180 |
Why?
|
| Gray Matter | 2 | 2022 | 50 | 0.180 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 2304 | 0.180 |
Why?
|
| Nutrition Surveys | 3 | 2015 | 338 | 0.180 |
Why?
|
| Ascorbic Acid | 1 | 2002 | 72 | 0.180 |
Why?
|
| Urbanization | 1 | 2022 | 10 | 0.180 |
Why?
|
| Regression Analysis | 3 | 2010 | 761 | 0.180 |
Why?
|
| Oligodendroglia | 1 | 2022 | 96 | 0.180 |
Why?
|
| Dementia | 3 | 2024 | 436 | 0.180 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2024 | 325 | 0.170 |
Why?
|
| Time Factors | 4 | 2020 | 6196 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 1267 | 0.170 |
Why?
|
| Elder Abuse | 1 | 2001 | 25 | 0.170 |
Why?
|
| Primary Health Care | 1 | 2007 | 775 | 0.160 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2020 | 8 | 0.160 |
Why?
|
| Angiotensinogen | 2 | 2010 | 24 | 0.160 |
Why?
|
| Depression | 1 | 2009 | 1320 | 0.160 |
Why?
|
| Wakefulness | 1 | 2020 | 103 | 0.150 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2020 | 23 | 0.150 |
Why?
|
| Antioxidants | 1 | 2002 | 331 | 0.150 |
Why?
|
| Attention | 2 | 2018 | 194 | 0.150 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 450 | 0.150 |
Why?
|
| Cerebrospinal Fluid | 1 | 2020 | 99 | 0.150 |
Why?
|
| Prospective Studies | 4 | 2017 | 6459 | 0.150 |
Why?
|
| Sex Factors | 2 | 2015 | 1356 | 0.150 |
Why?
|
| Pilot Projects | 3 | 2023 | 1445 | 0.150 |
Why?
|
| Models, Neurological | 2 | 2018 | 212 | 0.150 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 732 | 0.150 |
Why?
|
| Analysis of Variance | 3 | 2010 | 928 | 0.150 |
Why?
|
| Signal Detection, Psychological | 1 | 2019 | 11 | 0.140 |
Why?
|
| Early Diagnosis | 1 | 2019 | 195 | 0.140 |
Why?
|
| Organ Size | 1 | 2019 | 407 | 0.140 |
Why?
|
| Lipids | 1 | 2002 | 569 | 0.140 |
Why?
|
| Microglia | 1 | 2020 | 147 | 0.140 |
Why?
|
| Risk Assessment | 4 | 2010 | 3711 | 0.140 |
Why?
|
| Health Surveys | 3 | 2006 | 261 | 0.140 |
Why?
|
| Preliminary Data | 1 | 2018 | 8 | 0.140 |
Why?
|
| Systole | 2 | 2009 | 195 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2020 | 711 | 0.140 |
Why?
|
| Facial Recognition | 1 | 2018 | 6 | 0.130 |
Why?
|
| Myocardial Ischemia | 1 | 2020 | 307 | 0.130 |
Why?
|
| Prefrontal Cortex | 1 | 2020 | 215 | 0.130 |
Why?
|
| Association Learning | 1 | 2018 | 20 | 0.130 |
Why?
|
| Mental Status Schedule | 1 | 2017 | 43 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 2 | 2020 | 1075 | 0.130 |
Why?
|
| Astrocytes | 1 | 2020 | 264 | 0.130 |
Why?
|
| Hippocampus | 2 | 2019 | 806 | 0.130 |
Why?
|
| Sleep | 1 | 2020 | 381 | 0.130 |
Why?
|
| South Carolina | 2 | 2007 | 10 | 0.130 |
Why?
|
| Quality of Life | 1 | 2007 | 2082 | 0.130 |
Why?
|
| Severity of Illness Index | 4 | 2008 | 3061 | 0.120 |
Why?
|
| Genotype | 2 | 2015 | 2595 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2003 | 919 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 707 | 0.120 |
Why?
|
| Activities of Daily Living | 2 | 2009 | 386 | 0.120 |
Why?
|
| Contrast Media | 1 | 2020 | 474 | 0.120 |
Why?
|
| Georgia | 1 | 2016 | 46 | 0.120 |
Why?
|
| Electroencephalography | 1 | 2020 | 863 | 0.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2002 | 744 | 0.110 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 154 | 0.110 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2015 | 32 | 0.110 |
Why?
|
| Tidal Volume | 1 | 2015 | 42 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2020 | 804 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2017 | 295 | 0.110 |
Why?
|
| Awareness | 2 | 2006 | 78 | 0.110 |
Why?
|
| Memory, Short-Term | 1 | 2016 | 138 | 0.110 |
Why?
|
| Blood-Brain Barrier | 1 | 2015 | 153 | 0.110 |
Why?
|
| Health Services Needs and Demand | 2 | 2006 | 179 | 0.100 |
Why?
|
| Rest | 1 | 2014 | 64 | 0.100 |
Why?
|
| Young Adult | 3 | 2025 | 10103 | 0.100 |
Why?
|
| Microcirculation | 2 | 2011 | 104 | 0.100 |
Why?
|
| Survival Analysis | 2 | 2009 | 1483 | 0.100 |
Why?
|
| Plaque, Amyloid | 1 | 2013 | 65 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2020 | 948 | 0.090 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2013 | 56 | 0.090 |
Why?
|
| Accidental Falls | 2 | 2011 | 112 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2020 | 934 | 0.090 |
Why?
|
| Electrocardiography | 1 | 2018 | 970 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2017 | 17753 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 523 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 853 | 0.090 |
Why?
|
| Retinal Vessels | 1 | 2011 | 48 | 0.080 |
Why?
|
| Telemetry | 1 | 2010 | 23 | 0.080 |
Why?
|
| Housing for the Elderly | 1 | 2010 | 2 | 0.080 |
Why?
|
| Receptors, Angiotensin | 1 | 2010 | 20 | 0.080 |
Why?
|
| Monitoring, Ambulatory | 1 | 2010 | 60 | 0.080 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2010 | 112 | 0.080 |
Why?
|
| Sweden | 1 | 2009 | 39 | 0.070 |
Why?
|
| Retinal Diseases | 1 | 2011 | 142 | 0.070 |
Why?
|
| Atrophy | 1 | 2009 | 247 | 0.070 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2009 | 161 | 0.070 |
Why?
|
| Peer Review | 2 | 2007 | 34 | 0.070 |
Why?
|
| Clinical Protocols | 1 | 2009 | 230 | 0.070 |
Why?
|
| Gene Frequency | 1 | 2010 | 729 | 0.070 |
Why?
|
| Brain Mapping | 1 | 2010 | 384 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 1071 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2006 | 789 | 0.070 |
Why?
|
| Phenotype | 2 | 2026 | 4497 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2011 | 1410 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 587 | 0.070 |
Why?
|
| Body Composition | 1 | 2010 | 545 | 0.070 |
Why?
|
| Homeostasis | 2 | 2022 | 712 | 0.060 |
Why?
|
| Southeastern United States | 1 | 2007 | 35 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2010 | 767 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 376 | 0.060 |
Why?
|
| Education, Nursing, Continuing | 1 | 2007 | 20 | 0.060 |
Why?
|
| Observer Variation | 1 | 2008 | 311 | 0.060 |
Why?
|
| Disability Evaluation | 1 | 2007 | 191 | 0.060 |
Why?
|
| AC133 Antigen | 1 | 2026 | 34 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2026 | 57 | 0.060 |
Why?
|
| Total Quality Management | 1 | 2006 | 22 | 0.060 |
Why?
|
| Antigens, CD34 | 1 | 2026 | 97 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 1173 | 0.060 |
Why?
|
| Lysophosphatidylcholines | 1 | 2025 | 13 | 0.060 |
Why?
|
| Receptors, CXCR4 | 1 | 2026 | 70 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 915 | 0.060 |
Why?
|
| Diastole | 1 | 2026 | 181 | 0.060 |
Why?
|
| Preventive Health Services | 1 | 2006 | 59 | 0.060 |
Why?
|
| Nurse Practitioners | 1 | 2006 | 50 | 0.060 |
Why?
|
| Dementia, Vascular | 1 | 2005 | 14 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 1295 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2007 | 447 | 0.050 |
Why?
|
| Biomechanical Phenomena | 1 | 2025 | 279 | 0.050 |
Why?
|
| Asymptomatic Diseases | 1 | 2024 | 77 | 0.050 |
Why?
|
| Comorbidity | 1 | 2009 | 1595 | 0.050 |
Why?
|
| Animals | 4 | 2022 | 33912 | 0.050 |
Why?
|
| Allied Health Personnel | 1 | 2004 | 33 | 0.050 |
Why?
|
| Telemedicine | 1 | 2010 | 526 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2007 | 824 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2006 | 297 | 0.050 |
Why?
|
| Cholesterol, HDL | 1 | 2005 | 383 | 0.050 |
Why?
|
| Health Policy | 1 | 2006 | 234 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2003 | 272 | 0.050 |
Why?
|
| Probability | 1 | 2003 | 306 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2026 | 541 | 0.050 |
Why?
|
| Diuretics | 1 | 2004 | 159 | 0.050 |
Why?
|
| Program Development | 1 | 2004 | 179 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2004 | 132 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2023 | 83 | 0.050 |
Why?
|
| Headache | 1 | 2023 | 107 | 0.050 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2022 | 17 | 0.050 |
Why?
|
| Autopsy | 1 | 2022 | 111 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2023 | 238 | 0.050 |
Why?
|
| Drug Repositioning | 1 | 2022 | 32 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 191 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2022 | 149 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2006 | 645 | 0.040 |
Why?
|
| Neuroprotection | 1 | 2022 | 31 | 0.040 |
Why?
|
| Biological Transport | 1 | 2022 | 329 | 0.040 |
Why?
|
| Patient Selection | 1 | 2006 | 729 | 0.040 |
Why?
|
| Health Education | 1 | 2004 | 228 | 0.040 |
Why?
|
| Myelin Sheath | 1 | 2022 | 131 | 0.040 |
Why?
|
| Adolescent | 2 | 2022 | 20987 | 0.040 |
Why?
|
| Bias | 1 | 2002 | 151 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2022 | 258 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2002 | 276 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2005 | 604 | 0.040 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2001 | 13 | 0.040 |
Why?
|
| Potassium, Dietary | 1 | 2001 | 13 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2022 | 223 | 0.040 |
Why?
|
| Wisconsin | 1 | 2001 | 17 | 0.040 |
Why?
|
| Rats, Transgenic | 1 | 2020 | 17 | 0.040 |
Why?
|
| Sleep Stages | 1 | 2020 | 30 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2003 | 1211 | 0.040 |
Why?
|
| Magnesium | 1 | 2001 | 114 | 0.040 |
Why?
|
| Mass Screening | 1 | 2006 | 822 | 0.040 |
Why?
|
| Independent Living | 2 | 2011 | 64 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2022 | 238 | 0.040 |
Why?
|
| Heterozygote | 1 | 2022 | 737 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 304 | 0.040 |
Why?
|
| Sample Size | 1 | 2020 | 84 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2007 | 2904 | 0.040 |
Why?
|
| Echocardiography | 1 | 2026 | 1125 | 0.040 |
Why?
|
| Urban Population | 1 | 2022 | 287 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2007 | 1050 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2022 | 393 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2001 | 563 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 350 | 0.040 |
Why?
|
| Rural Population | 1 | 2022 | 276 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2020 | 192 | 0.040 |
Why?
|
| Models, Animal | 1 | 2020 | 450 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 357 | 0.030 |
Why?
|
| Proteome | 1 | 2020 | 285 | 0.030 |
Why?
|
| Neurogenesis | 1 | 2020 | 206 | 0.030 |
Why?
|
| Functional Neuroimaging | 1 | 2017 | 30 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2001 | 1378 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 373 | 0.030 |
Why?
|
| Alleles | 1 | 2022 | 1673 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 1998 | 274 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 1998 | 243 | 0.030 |
Why?
|
| Incidence | 1 | 2005 | 3360 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2017 | 311 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2022 | 1801 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 1998 | 589 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 1240 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1489 | 0.030 |
Why?
|
| Rats | 1 | 2020 | 3370 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1998 | 544 | 0.030 |
Why?
|
| Mice | 2 | 2022 | 18301 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2020 | 951 | 0.020 |
Why?
|
| Prognosis | 1 | 2002 | 4886 | 0.020 |
Why?
|
| Neurons | 1 | 2022 | 1979 | 0.020 |
Why?
|
| Boston | 1 | 2011 | 117 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2011 | 110 | 0.020 |
Why?
|
| Licensure | 1 | 2010 | 14 | 0.020 |
Why?
|
| Computer Communication Networks | 1 | 2010 | 17 | 0.020 |
Why?
|
| Prejudice | 1 | 2010 | 39 | 0.020 |
Why?
|
| State Government | 1 | 2010 | 33 | 0.020 |
Why?
|
| Reimbursement Mechanisms | 1 | 2010 | 36 | 0.020 |
Why?
|
| Government Regulation | 1 | 2010 | 44 | 0.020 |
Why?
|
| Confidentiality | 1 | 2010 | 108 | 0.020 |
Why?
|
| Personal Autonomy | 1 | 2010 | 208 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2010 | 223 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 555 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2011 | 460 | 0.020 |
Why?
|
| Informed Consent | 1 | 2010 | 351 | 0.020 |
Why?
|
| Teaching Materials | 1 | 2007 | 18 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2007 | 225 | 0.020 |
Why?
|
| Benchmarking | 1 | 2007 | 137 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 198 | 0.010 |
Why?
|
| Forecasting | 1 | 2007 | 351 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2010 | 712 | 0.010 |
Why?
|
| Faculty, Medical | 1 | 2007 | 281 | 0.010 |
Why?
|
| Curriculum | 1 | 2007 | 798 | 0.010 |
Why?
|
| Mycoses | 1 | 1998 | 110 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1998 | 327 | 0.010 |
Why?
|
| Health Care Costs | 1 | 1998 | 407 | 0.010 |
Why?
|